Allantoin as an independent marker associated with carotid intima-media thickness in subclinical atherosclerosis

M.S. Santana¹, K.P. Nascimento¹, P.A. Lotufo²,³, I.M. Benseñor²,³ and F.C. Meotti¹

¹Departamento de Bioquímica, Instituto de Química, Universidade de São Paulo, São Paulo, SP, Brasil
²Centro de Pesquisa Clínica e Epidemiológica, Hospital Universitário, Universidade de São Paulo, São Paulo, SP, Brasil
³Departamento de Medicina, Escola de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil

Abstract

Allantoin is the main product of uric acid oxidation and was found to be augmented in atherosclerotic plaque in human autopsy and in animal models of atherosclerosis. Uric acid is abundant in human plasma and is prone to oxidation in inflammatory conditions such as atherosclerosis. In this study, we found a significant increase in plasma uric acid (P=0.002) and allantoin (P=0.025) in participants of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) that presented common carotid intima-media thickness (c-IMT) within the 75th percentile (c-IMT ≥ P75). Multiple linear regression showed an association of c-IMT with uric acid (β=0.0004, P=0.014) and allantoin (β=0.018, P=0.008). This association was independent of age, the traditional risk factor LDL/HDL ratio, and non-traditional risk factors: pulse pressure, neck circumference, and the inflammatory marker myeloperoxidase. The independent and strong association of allantoin with c-IMT shows that it might be a useful marker, along with other traditional risk factors, to evaluate an early stage of atherosclerosis.

Key words: Allantoin; Uric acid; Common carotid intima-media thickness; Atherosclerosis; Oxidation

Introduction

Increased levels of serum uric acid have been suggested as a possible predictor for cardiovascular disease (CVD) (1,2). Epidemiological studies have demonstrated a link between hyperuricemia (serum uric acid > 7 mg/dL) and hypertension, kidney disease, and other risk factors for CVD, like obesity and metabolic syndrome (2,3). Serum uric acid has been associated with carotid intima-media thickness (c-IMT) and coronary artery disease (4,5). However, debate continues whether hyperuricemia predicts CVD risk independently or merely reinforces classical CVD risk factors (2,6). The increased level of uric acid in atherosclerosis has been suggested as a defense mechanism against oxidative stress because uric acid is an important serum antioxidant (7). In fact, uric acid is the main substrate for oxidation by peroxidases in plasma (8). The oxidation of uric acid by peroxidases or by oxidants yielded during inflammation generates allantoin as the main final product (9,10). Therefore, the measurement of allantoin rather than uric acid alone could indicate vascular damage related to inflammation and oxidative stress in atherosclerosis (9,11).

Substantial amount of allantoin has been found in human atherosclerotic plaques (12,13). Importantly, the degree of atherosclerosis in knockout mice prone to atherosclerosis was positively associated with urinary excretion of allantoin (14). In spite of the evidence, clinical studies that correlate plasma allantoin levels and atherosclerosis are scarce. Allantoin could be a true marker for atherosclerosis especially in the initial steps of the process when other risk factors still have weak associations. In this study, we investigated the association of uric acid and allantoin with c-IMT. We found that both metabolites were significantly associated with c-IMT independently of classical risk factors of atherosclerosis.

Material and Methods

Study population

A total of 35 men with c-IMT scored within the 75th percentile (c-IMT ≥ P75) and another 35 men with c-IMT below the 75th percentile (c-IMT < P75), all apparently healthy, were randomly selected from the serum bank of the Brazilian Longitudinal Study for Adult Health (ELSA-Brasil) project. None presented a c-IMT higher than 1 mm to ensure the inclusion of subclinical atherosclerosis.
cases only. Groups were paired according to race and diagnosis of hypertension and diabetes. 

ELSA-Brasil is a multicenter cohort study of 15,105 living in 6 Brazilian cities (São Paulo, Rio de Janeiro, Porto Alegre, Belo Horizonte, Vitória, and Salvador), aimed at investigating biological and social determinants of cardiovascular diseases and diabetes. During baseline evaluation (2008–2010), the diagnoses of hypertension, diabetes, dyslipidemia, and regular use of medicines were confirmed, uric acid was measured, and the common c-IMT was determined. Subjects under use of uricosuric drugs, with body mass index ≥30, glomerular filtration rate ≤70 mL/min were not eligible for randomization. The study conformed to the Declaration of Helsinki. All participants agreed to participate in the study and signed an informed consent form. The study was approved by the Institutional Review Board of the Universidade de São Paulo (Brazil). All samples were analyzed by the double-blinded method.

**Laboratory analysis**

Heparinized plasma samples were collected and frozen at −80°C. Details about proceedings at ELSA-Brasil central laboratory and biobank are described in detail elsewhere (15).

**Quantification of plasma uric acid and allantoin**

Uric acid was extracted from 200 μL plasma, mixing with 600 μL of cold acetonitrile. The samples were centrifuged at 22,000 g for 15 min at 4°C and the sediment was re-extracted with 600 μL cold acetonitrile/10 mM phosphate buffer, pH 7.4 (1:1). The combined supernatants were immediately applied to an AG 1-X8 anion-exchange resin column. The purified sample was dried under nitrogen atmosphere at 60°C. The resulting residue was dissolved in 200 μL of 0.1 M NaOH and heated in boiling water bath for 20 min to hydrolyze allantoin to allantoate. Then, 300 μL of 1.5 mM 2,4-dinitrophenylhydrazine/2.5 M HCl was added for derivatization and subsequent incubation at 50°C for 50 min. The reaction mixture was dried, filtered, and injected (40 μL) onto a C18(2) Luna (25 × 4.6 mm, 5 μm particle size) column (Phenomenex, USA). The mobile phase constituted of 8.3 mM phosphate buffer in 5% acetonitrile, pH 6.1 (solvent A) and 8.3 mM phosphate buffer in 50% acetonitrile, pH 6.1 (solvent B), with a constant flow of 0.5 mL/min. The following gradient was used: 0.01 to 10 min of 5% solvent B; 10–12 min of 60% solvent B; 12–30 min of 100% solvent B; 30–32 min of 5% solvent B. The column was equilibrated for 10 min with 5% solvent B. Derivatized allantoin was detected at 360 nm. The quantification was obtained by plotting the peak area against a standard curve of allantoin (0.5–10 μM).

**Myeloperoxidase assay**

Myeloperoxidase concentration was measured by sandwich enzyme-linked immunosorbent assay (ELISA) (Abcam, UK). Briefly, sample proteins were quantified and diluted to normalize them before reaction. Myeloperoxidase was captured in a 96-well plate impregnated with mouse monoclonal antibody. After incubation, a polyclonal antibody was added and the excess was washed with phosphate-buffered saline. Avidin-biotin peroxidase complex was added and the excess was washed with phosphate-buffered saline. The peroxidase substrate tetramethylbenzidine was added to reveal avidin-biotin binding. Myeloperoxidase concentration was detected at 450 nm and compared against a standard curve.

**Biochemical measurements and physical parameters**

Body mass index was obtained by dividing the weight (kg) by the square of height (m) (3). Plasma glucose was measured by enzymatic hexokinase method using the ADVIA 1200 Siemens analyzer (Siemens, USA). Glycosylated hemoglobin (HbA1c) was measured by HPLC using the Bio-Rad Variant II HbA1C analyzer (Hercules, USA). Low density lipoprotein (LDL)-cholesterol and high density lipoprotein (HDL)-cholesterol were determined by a homogeneous colormetric method without precipitation. Hypertension was defined as the use of medications to treat hypertension, systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg. Diabetes was defined as having a medical history of diabetes, use of medications to treat diabetes, a fasting glucose ≥126 mg/dL, glycated hemoglobin (HbA1C) levels ≥6.5% or a 2-h oral glucose tolerance test ≥200 mg/dL (17).
c-IMT measurements
The technique for c-IMT measurement has been previously applied in population-based studies including the ELSA-Brasil (18). The protocol was performed using a Toshiba ultrasound system (Aplio XG™, USA) with a 7.5 MHz linear transducer. c-IMT was measured in the outer wall of a pre-defined carotid segment of 1 cm in length from 1 cm below carotid bifurcation during three cardiac cycles. The carotid images during three cardiac cycles were obtained and sent to the centralized reading center in São Paulo. We used MIA™ software to standardize the reading and interpretation of carotid scans as previously described. c-IMT measurements are reported as the maximum values for the thickness of the right and left arteries measured at the far wall (17).

Statistical analysis
All continuous variables are reported as means ± SD. Categorical variables are reported as numbers and proportions. Comparison between the two groups (c-IMT ≥ P75 and c-IMT < P75) was performed by unpaired t-test. Associations were evaluated using multiple linear regression, analysis of variance (ANOVA). Statistical analyses were performed using SPSS version 17 software (SPSS Inc., USA) or GraphPad Prism 5.0. Results were considered statistically significant when P was <0.05.

Results
Individuals in this study were all male, 45 to 60 years old, and with c-IMT lower than 1 mm to ensure analysis of an early process of atherosclerosis. Table 1 compares the demographic and clinical characteristics according to c-IMT ≥ P75 and c-IMT < P75 groups. The parameters race, use of anti-hypertensive drugs, and diabetes were equally distributed in the two groups. Traditional markers such as LDL, HDL, and BMI, and two potential novel markers, neck circumference and pulse pressure (17), were very similar among groups.

A significant increase in the levels of uric acid (P=0.002) and allantoin (P=0.025) was found in the c-IMT ≥ P75 group (Table 1). Therefore, we next performed a multiple linear regression to evaluate the association between uric acid and allantoin with c-IMT. The analysis was adjusted by age, by the traditional risk factor LDL/HDL ratio, by the non-traditional risk factors pulse pressure and neck circumference, and by the inflammatory marker myeloperoxidase. The multiple linear regression revealed a significant association of c-IMT with uric acid and an even stronger association with allantoin. Of relevance, this positive association was independent of traditional and non-traditional risk factors of CVD (Table 2). It is important to highlight that the aim of this study was to

| Characteristic                        | c-IMT ≥ P75 (n=35) | c-IMT < P75 (n=35) |
|--------------------------------------|--------------------|--------------------|
| c-IMT mm, mean (range)              | 0.75 (0.61–1.02)   | 0.55 (0.25–0.7)    |
| Age, years (mean)                   | 51.9               | 48.8               |
| Race/ethnicity (n, %)               |                    |                    |
| White (n=41)                        | 19 (54.3)          | 22 (62.9)          |
| Mixed (n=15)                        | 8 (22.9)           | 7 (20)             |
| Black (n=10)                        | 6 (17.1)           | 4 (11.4)           |
| Asian (n=4)                         | 2 (5.7)            | 2 (5.7)            |
| Body mass index (kg/m²)             | 25.8 ± 0.6         | 24.6 ± 0.5         |
| Under anti-hypertensive medicine (n, %) | 10 (28.6)       | 5 (14.3)           |
| Diabetes (n, %)                     | 10 (28.6)          | 7 (20)             |
| Use of lipid-lowering agents (n, %)  | 4 (11.4)           | 2 (5.7)            |
| Fasting plasma glucose (mg/dL)      | 122 ± 52.1         | 110.3 ± 10.1       |
| HbA1c (%)                            | 5.8 ± 1.5          | 5.4 ± 0.6          |
| LDL-cholesterol (mg/dL)             | 136.8 ± 38.9       | 135 ± 36           |
| HDL-cholesterol (mg/dL)             | 55.5 ± 15.0        | 51.4 ± 13.6        |
| LDL/HDL (mg/dL)                     | 2.6 ± 0.9          | 2.8 ± 0.92         |
| Neck circumference (cm)             | 38.4 ± 2.6         | 37.7 ± 2.2         |
| Pulse pressure (mmHg)               | 44.24 ± 8.3        | 44.6 ± 7.9         |
| MPO (ng/mL)                         | 31.09 ± 16.1       | 28.17 ± 14.0       |
| Uric acid (µmol/L)                  | 296.27 ± 91.21     | 232.99 ± 75.43*    |
| Allantoin (µmol/L)                  | 4.11 ± 2.55        | 2.75 ± 2.06*       |

Plasma measurements are reported as means ± SD. *P <0.05 by unpaired t-test. c-IMT: carotid intima-media-thickness; HbA1c: glycosylated hemoglobin A; LDL: low-density lipoprotein; HDL: high-density lipoprotein; MPO: myeloperoxidase.
evaluate a very initial process of atherogenesis and, therefore, the individuals of the study were apparently healthy, within normal BMI, LDL, HDL, and fasting glucose levels.

**Discussion**

The association of serum uric acid with CVD, including subclinical atherosclerosis, has been demonstrated elsewhere (1,3–5,19). However, debate continues whether uric acid has indeed a causal role and could, therefore, be an independent factor to CVD. For instance, three independent studies showed that serum uric acid was associated with subclinical atherosclerosis (1,4,19), but a Mendelian randomization analysis showed that the causal effect of uric acid could be inflated by hidden pleiotropy (6). In the present study, the association of uric acid and its oxidation product allantoin was independent of LDL/HDL ratio, pulse pressure, and neck circumference. As previously reported, pulse pressure and neck circumference have presented a higher impact on c-IMT than traditional risk factors, including lipoproteins (17).

The dual anti- or pro-oxidant property of uric acid has generated discussions whether it is protective or harmful. Uric acid is considered the main antioxidant in human plasma (7). However, the purine metabolism during uric acid production by xanthine oxidase generates the free radical superoxide and hydrogen peroxide (20). In addition, the neutralization of reactive oxygen species by uric acid does not necessarily produce inert yields. For instance, the neutralization of hydrogen peroxide occurs by a peroxidase-catalyzed reaction and this produces extremely reactive species, including urate free radical and urate hydroperoxide (9,10). Therefore, the vascular oxidation of uric acid could contribute to tissue damage and to the inflammatory process (Figure 1). The main breakdown product of these reactive uric acid-derivative species is allantoin (9,10). Allantoin has been proposed as a

| Parameter       | B     | 95%CI           | P     |
|-----------------|-------|----------------|-------|
| Age             | 0.011 | 0.005 to 0.017 | <0.001*|
| LDL/HDL         | 0.013 | -0.018 to 0.044| 0.397 |
| Neck circumference | 0.008 | -0.005 to 0.020| 0.095 |
| Pulse pressure  | -0.002| -0.006 to 0.001| 0.112 |
| MPO             | 0.000 | 0.001 to -0.002| 0.803 |
| Uric acid       | 0.0004| 0.0001 to 0.001| 0.014*|
| Allantoin       | 0.018 | 0.005 to 0.031 | 0.008*|

Data are reported as the regression coefficient (B) and 95%CI. *P<0.05. Each parameter was adjusted against all the other parameters presented in this table. c-IMT: carotid intima-media-thickness; LDL: low-density lipoprotein; HDL: high-density lipoprotein; MPO: myeloperoxidase.

**Table 2.** Multiple linear regression between c-IMT and different parameters.

---

*Figure 1.* Uric acid reacts with oxidants from inflammatory cells in atheroma plaque. The oxidation of uric acid by hydrogen peroxide is catalyzed by inflammatory peroxidases, mainly myeloperoxidase, to generate urate free radical. The combination of this free radical with superoxide (O$_2^*$) yields urate hydroperoxide. Both urate free radical and urate hydroperoxide are much stronger oxidants than hydrogen peroxide and superoxide and can easily oxidize neighboring molecules increasing tissue damage and inflammation. Allantoin is the main end-product of these reactions and, thus, allantoin plasma levels are directly correlated with the oxidation of uric acid. Therefore, plasma allantoin is an indicative of the oxidative stress in the intima layer and could be useful in the prediction of the very initial process of atherosclerosis.
biomarker for oxidative stress (11,16). The levels of this metabolite were augmented in patients with chronic renal failure (16) and a substantial amount of allantoin was found in atheroma plaque (12,13). Increased urinary excretion of allantoin was also associated with the degree of atherosclerosis in mice (14). In this study, we found a significant strong association between allantoin and c-IMT, showing that allantoin could be a relevant marker in the early process of vascular disease. In spite of allantoin being a true marker for uric acid oxidation and oxidative stress in inflammatory conditions, this is the first study, to our best knowledge, that correlates allantoin with subclinical atherosclerosis.

We could not detect any correlation between c-IMT with plasma myeloperoxidase. Even though myeloperoxidase is an important enzyme related to inflammation, cardiovascular disease, and uric acid oxidation (9), it is not the only peroxidase present in plasma and is likely not the solely responsible for uric acid oxidation in plasma. In summary, the present study demonstrated that plasma uric acid and allantoin were significantly and independently correlated with common c-IMT. These results showed that oxidation of uric acid and production of allantoin was a key event in subclinical atherosclerosis. Therefore, the measurement of allantoin in plasma, along with other traditional factors, could emerge as a relevant marker in subclinical atherosclerosis.

Acknowledgments

We would like to thank Dr. Paolo Di Mascio and Dr. Marisa Helena Gennari de Medeiros from the Institute of Chemistry, University of São Paulo, for their laboratory and equipment support, Fernanda Manso Prado and Marcos Felipe Pinatto Botelho for technical assistance, and Dr. Francisco Rafael Laurindo for discussion and assistance in the editing of this paper. This study was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, CEPID-Redoxoma #2013/07937-8 and Young Investigator Award #2011/18106-4); Conselho Nacional de Pesquisa e Desenvolvimento Tecnológico (CNPq #472105/2012-4); Ministério Brasileiro da Saúde and Ministério Brasileiro da Ciência e Tecnologia (FINEP #0115.00 SP).

References

1. Wang H, Jacobs DR Jr, Gaffo AL, Gross MD, Goff DC Jr, Carr JJ. Longitudinal association between serum urate and subclinical atherosclerosis: the Coronary Artery Risk Development in Young Adults (CARDIA) study. J Intern Med 2013; 274: 594–609, doi: 10.1111/joim.12120.
2. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med, 2008; 359:1811–1821, doi: 10.1056/NEJMr0800885.
3. Lotufo PA, Baena CP, Santos IS, Bensenor IM. Serum uric acid and prehypertension among adults free of cardiovascular diseases and diabetes: Baseline of the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Angiology 2015; 67: 180–186, doi: 10.1177/000331971558037.
4. Gur M, Sahin DY, Elbasan Z, Kalkan GY, Yildiz A, Kaya Z, et al. Uric acid and high sensitive C-reactive protein are associated with subclinical thoracic aortic atherosclerosis. J Cardio 2013: 61: 144–148, doi: 10.1016/j.jcc.2012.08.023.
5. Gur M, Yilmaz R, Demirbag R, Aksoy N. Relation of serum uric acid levels with the presence and severity of angiographic coronary artery disease. Angiology 2008; 59: 166–171, doi: 10.1177/0003319706292010.
6. White J, Sofat R, Hemani G, Shah T, Engmann J, Dale C, et al. Plasma urate concentration and risk of coronary heart disease: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol 2016; 4: 327–336, doi: 10.1016/S2213-8587 (15)00380-1.
7. Becker BF. Towards the physiological function of uric acid. Free Radic Biol Med 1993; 14: 615–631, doi: 10.1016/0891-5849(93)90143-I.
8. Padiglia A, Medda R, Longu S, Pedersen JZ, Floris G. Uric acid is a main electron donor to peroxidases in human blood plasma. Med Sci Monit 2002; 8: BR454–BR459.

9. Meotti FC, Jameson GN, Turner R, Hanwood DT, Stockwell S, Rees MD, et al. Urate as a physiological substrate for myeloperoxidase: implications for hyperuricemia and inflammation. J Biol Chem 2011; 286: 12901–12911, doi: 10.1074/jbc.M110.172460.
10. Patricio ES, Prado FM, da Silva RP, Carvalho LA, Prates MV, Dadamos T, et al. Chemical characterization of urate hydroperoxide, a pro-oxidant intermediate generated by urate oxidation in inflammatory and photo-induced processes. Chem Res Toxicol 2015; 28: 1556–1566, doi: 10.1021/acs.chemrestox.5b00132.
11. Grootveld M, Halliwell B. Measurement of allantoin and uric acid in human-body fluids - a potential index of free-radical reactions in vivo. Biochem J, 1987; 243: 803–808, doi: 10.1042/ bj2430803.
12. Terzuoli L, Marinello E, Felici C, Frois B, Setacci C, Giubbolini M, et al. Purine bases and atheromatous plaque. Int J Immunopathol Pharmacol 2004; 17(3 Suppl): 31–33.
13. Clari I, Terzuoli L, Porcelli B, Coppola MG, Marinello E. Antioxidant status and purine bases in carotid artery plaque. Nucleosides Nucleotides Nucleic Acids, 2008; 27: 624–627, doi: 10.1080/15257770802138608.
14. Li D, Zhang L, Dong F, Liu Y, Li N, Li H, et al. Metabonomic changes associated with atherosclerosis progression for LDLR(−/−) mice. J Proteome Res 2015; 14: 2237–2254, doi: 10.1021/acs.jproteome.5b00032.
15. Pereira AC, Bensenor IM, Fedeli LM, Castilhos C, Vidigal PG, Maniero V, et al. Design and implementation of the SELSA-Brasil biobank: a prospective study in a Brazilian population. Rev Saude Publica, 2013; 47(Suppl 2): 72–78, doi: 10.1590/S0034-8910.2013047003822.
16. Kand’ar R, Zakova P, Muzaková V. Monitoring of antioxidant properties of uric acid in humans for a consideration
measuring of levels of allantoin in plasma by liquid chromatography. Clin Chim Acta 2006; 365: 249–256, doi: 10.1016/j.cca.2005.09.002.

17. Santos IS, Alencar AP, Rundek T, Goulart AC, Barreto SM, Pereira AC, et al. Low impact of traditional risk factors on carotid intima-media thickness: the ELSA-Brasil cohort. Arterioscler Thromb Vasc Biol 2015; 35: 2054–2059, doi: 10.1161/ATVBAHA.115.305765.

18. Baena CP, Lotufo PA, Santos IS, Goulart AC, Bittencourt MS, Duncan BB, et al. Neck circumference is associated with carotid intimal-media thickness but not with coronary artery calcium: results from the ELSA-Brasil. Nutr Metab Cardiovasc Dis 2016; 26: 216–222, doi: 10.1016/j.numecd.2016.01.004.

19. Oikonen M, Wendelin-Saarenhovi M, Lyytikainen LP, Siltanen N, Loo BM, Jula A, et al. Associations between serum uric acid and markers of subclinical atherosclerosis in young adults. The cardiovascular risk in Young Finns study. Atherosclerosis 2012; 223: 497–503, doi: 10.1016/j.atherosclerosis.2012.05.036.

20. Kelley EE, Khoo NK, Hundley NJ, Malik UZ, Freeman BA, Tarpey MM. Hydrogen peroxide is the major oxidant product of xanthine oxidase. Free Radic Bio Med 2010; 48: 493–498, doi: 10.1016/j.freeradbiomed.2009.11.012.